N-(p-methoxybenzyl)-O-(p-methoxybenzyl)hydroxylamine | 5555-64-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: N-(p-methoxybenzyl)-O-(p-methoxybenzyl)hydroxylamine
• 英文别名: O,N-Bis-<4-methoxy-benzyl>-hydroxylamin；O,N-Bis-(4-methoxy-benzyl)-hydroxylamin；1-(4-methoxyphenyl)-N-[(4-methoxyphenyl)methoxy]methanamine
• CAS: 5555-64-6
• 化学式: C₁₆H₁₉NO₃
• 分子量: 273.332
• InChiKey: PNWCJLFRYRHCFB-UHFFFAOYSA-N

物化性质

• 熔点：
  56-57 °C
• 沸点：
  413.3±55.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  39.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(p-methoxybenzyl)-O-(p-methoxybenzyl)hydroxylamine 在 三甲基铝 、 potassium carbonate 、 pyridinium chlorochromate 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 29.0h， 生成 <1R-(1α,2β,3α)>-1--N-(p-methoxybenzyl)hydroxycarboxamido>-3-(2-propyl)cyclopropane-2-carboxaldehyde
  参考文献：
  名称：

  Cyclopropanes as conformationally restricted peptide isosteres. Design and synthesis of novel collagenase inhibitors

  摘要：

  The 1,2,3-trisubstituted cyclopropane derivatives 9 and 10 were prepared as conformationally constrained analogues of the known collagenase inhibitor 8. The syntheses of 9 and 10 featured the highly enantioselective Rh2[S-MEPY]4 catalyzed cyclization of the, allylic diazo ester 11 to give the lactone 13. Opening of the lactone ring of 13 with N,O-di-(p-methoxybenzyl)hydroxylamine under Weinreb conditions followed by refunctionalization, coupling of the intermediate acid 16 with 17 and deprotection led to the dipeptide analogue 9. Alternatively, the lactone ring of 13 could be opened with the protected tyrosine 21 by a novel variant of the Weinreb protocol to give directly the dipeptide analogue 22 which was then converted into 10.

  DOI：

  10.1016/s0040-4020(01)90212-1
• 作为产物：
  描述：

  N-(4-Methoxy-benzyl)-N-(4-methoxy-benzoyl)-carbamidsaeure-ethylester 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 生成 N-(p-methoxybenzyl)-O-(p-methoxybenzyl)hydroxylamine
  参考文献：
  名称：

  羟胺衍生物的合成具有降胆固醇的活性。

  摘要：

  DOI：

  10.1021/jm00316a012

文献信息

• [EN] METALLOPROTEINASE INHIBITORS<br/>[FR] INHIBITEURS DE METALLOPROTEINASES
  申请人：BRITISH BIOTECH PHARM

  公开号：WO2004101537A1

  公开（公告）日：2004-11-25

  Compounds formula (IA) or (IB); wherein W represents HO(C=0)-, HONH(C=0)- or H(C=O)N(OH)-; X represents -O- or -S-; and R1, R2, and R3 are as defined in the description and claims, are inhibitors of matrix metalloproteinases, in particular MMP9 and/or MMP12.

  化合物的结构式（IA）或（IB）；其中，W代表HO(C=0)-，HONH(C=0)-或H(C=0)N(OH)-；X代表-O-或-S-；而R1、R2和R3如描述和权利要求中所定义的，是基质金属蛋白酶，特别是MMP9和/或MMP12的抑制剂。
• Hydroxamic acid derivatives as proteinase inhibitors
  申请人：British Biotech Pharmaceuticals Ltd.

  公开号：US20030050310A1

  公开（公告）日：2003-03-13

  Compounds of formula (I) are matrix metalloproteinase inhibitors wherein X represents a carboxylic acid group —COOH, or a hydroxamic acid group —CONHOH;R 2 represents a radical of formula (II): R 3 —(ALK) m —(Q) p —(ALK) n —, and W represents a cyclic amino radical of formula (IIIA) or (IIIB): 1

  公式（I）的化合物是基质金属蛋白酶抑制剂，其中X表示羧酸基- COOH或羟肟酸基- CONHOH；R2表示公式（II）的基团：R3-（ALK）m-（Q）p-（ALK）n-，W表示公式（IIIA）或（IIIB）的环状氨基基团：1。
• Oxa-and thiadiazoles and their use as metalloproteinase inhibitors
  申请人：Ayscough Paul Andrew

  公开号：US20050222189A1

  公开（公告）日：2005-10-06

  Compounds formula (IA) or (IB), wherein W represents HO(C═O)—, HONH(C═O)— or H(C═O)N(OH)—; X represents —O— or —S—; and R 1 , R 2 , and R 3 are as defined in the description and claims, are inhibitors of matrix metalloproteinases, in particular MMP9 and/or MMP12.

  化合物的公式（IA）或（IB），其中W代表HO（C═O）—，HONH（C═O）—或H（C═O）N（OH）—；X代表—O—或—S—；而R1，R2和R3如说明书和权利要求中所定义的，是基质金属蛋白酶的抑制剂，特别是MMP9和/或MMP12。
• OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS
  申请人：AYSCOUGH Andrew Paul

  公开号：US20080227833A1

  公开（公告）日：2008-09-18

  Compounds formula (IA) or (IB), wherein W represents HO(C═O)—, HONH(C═O)— or H(C═O)N(OH)—; X represents —O— or —S—; and R 1 , R 2 , and R 3 are as defined in the description and claims, are inhibitors of matrix metal oproteinases, in particular MMP9 and/or MMP12.

  化合物公式（IA）或（IB），其中W代表HO(C═O)—、HONH(C═O)—或H(C═O)N(OH)—；X代表—O—或—S—；而R1、R2和R3如描述和权利要求所定义的那样，是基质金属蛋白酶的抑制剂，特别是MMP9和/或MMP12。
• Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
  申请人：PFIZER INC.

  公开号：EP0818442A2

  公开（公告）日：1998-01-14

  A compound of the formula wherein n, p, q, X, Y, Z and Ar are as defined herein, useful in the treatment of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, scleritis or other diseases characterized by matrix metalloprotenase activity, as well as AIDS, sepsis, septic shock or other diseases involving the production of TNF.

  一种式中 n、p、q、X、Y、Z 和 Ar 如本文所定义的化合物，可用于治疗关节炎、癌症、组织溃疡、再狭窄、牙周病、表皮松解症、巩膜炎或其他以基质金属肽酶活性为特征的疾病，以及艾滋病、败血症、脓毒性休克或其他涉及 TNF 生成的疾病。